A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults
Robert P. McMahon(Valneva (Austria)), Juan Carlos Jaramillo(Valneva (Austria)), Nina Wressnigg(Valneva (Austria)), Romana Hochreiter(Valneva (Austria)), Martina Schneider(Valneva (Austria)), Susanne Eder-Lingelbach(Valneva (Austria)), Annegret Bitzer(Valneva (Austria)), Ulrike Fuchs(Valneva (Austria)), Michael Koren(Jacksonville University), Robert M. Mader(Valneva (Austria)), Vera Buerger(Valneva (Austria)), Katrin Dubischar(Valneva (Austria)), Sandra Hadl(Valneva (Austria)), Karin Kosulin(Valneva (Austria)), Oliver Zoihsl(Valneva (Austria))
Cited by 35
Related Papers
Drosophila Stardust is a partner of Crumbs in the control of epithelial cell polarity
|Nature|2001|273
Scavenger Receptor Class B Type I (SR-BI) Is Involved in Vitamin E Transport across the Enterocyte
|Journal of Biological Chemistry|2005|241